{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05669430",
            "orgStudyIdInfo": {
                "id": "GV20-0251-100"
            },
            "organization": {
                "fullName": "GV20 Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of GV20-0251 in Patients With Solid Tumor Malignancies",
            "officialTitle": "An Open-Label Study of GV20-0251 in Patients With Advanced and/or Refractory Solid Tumor Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-in-patients-with-solid-tumor-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-12",
            "studyFirstSubmitQcDate": "2022-12-21",
            "studyFirstPostDateStruct": {
                "date": "2022-12-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GV20 Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.",
            "detailedDescription": "This is a Phase 1 non-randomized, open label, multi-center study to be conducted in two parts (Parts A and B).\n\nPart A involves a 3 + 3 dose escalation scheme to evaluate safety and dose limiting toxicities and to establish the maximum tolerated dose and/or the recommended Phase 2 dose of GV20-0251.\n\nPart B consists of multiple expansion cohorts in which eligible participants will be treated at the recommended Phase 2 dose of GV20-0251 to further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of GV20-0251 as well as to evaluate anti-tumor activity in patients with selected malignancies.\n\nThe study consists of a Screening Period, a Treatment Period, an End of Treatment Visit, Safety Follow-Up Period and a Survival Follow-Up Period."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult",
                "Refractory Cancer",
                "Bladder Urothelial Carcinoma",
                "Cholangiocarcinoma",
                "Adenocarcinoma of the Colon",
                "Endometrial Carcinoma",
                "Head and Neck Carcinoma",
                "Cutaneous Melanoma",
                "Non-small Cell Lung Cancer",
                "Adenocarcinoma of the Rectum"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 268,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A - Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Part A involves a 3 + 3 dose escalation scheme to evaluate safety and dose limiting toxicities and to establish the maximum tolerated dose and/or the recommended Phase 2 dose of GV20-0251.",
                    "interventionNames": [
                        "Drug: GV20-0251"
                    ]
                },
                {
                    "label": "Part B - Multiple Expansion Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Part B consists of multiple expansion cohorts in which eligible participants will be treated at the recommended Phase 2 dose of GV20-0251 to further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of GV20-0251 as well as to evaluate anti-tumor activity in participants with selected malignancies.",
                    "interventionNames": [
                        "Drug: GV20-0251"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GV20-0251",
                    "description": "Increasing doses of GV20-0251 given intravenously as monotherapy.",
                    "armGroupLabels": [
                        "Part A - Dose Escalation"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "GV20-0251",
                    "description": "GV20-0251 RP2D given intravenously as monotherapy.",
                    "armGroupLabels": [
                        "Part B - Multiple Expansion Cohorts"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Evaluate the safety and tolerability of escalating doses of GV20-0251 in refractory advanced malignancy participants as defined in the protocol during dose escalation",
                    "description": "Number of participants with Dose Limiting Toxicities and Treatment Emergent Adverse/Serious Adverse Events",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part A: Establish the maximum tolerated dose and/or recommended Phase 2 dose of GV20-0251 in participants with advanced solid tumor malignancies",
                    "description": "Number of participants with Dose Limiting Toxicities and Treatment Emergent Adverse/Serious Adverse Events as well as integration of clinical laboratory, pharmacodynamic, pharmacokinetic, and preliminary efficacy endpoints",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part B: Evaluate the Overall Response Rate of GV20-0251.",
                    "description": "Overall Response Rate following GV20-0251 administration is defined as the proportion of efficacy-eligible participants who have a best response of complete response or partial response based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. A responder is defined as any participant who has a best overall response of complete response or partial response",
                    "timeFrame": "24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part A: Evaluate the Overall Response Rate (ORR) of GV20-0251.",
                    "description": "Overall Response Rate following GV20-0251 administration is defined as the proportion of efficacy-eligible participants who have a best response of complete response or partial response based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. A responder is defined as any participant who has a best overall response of complete response or partial response",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part B: Evaluate the safety of GV20-0251 in refractory advanced malignancy patients during Part B",
                    "description": "Number of participants with Treatment Emergent Adverse/Serious Adverse Events",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Part A & Part B: Measure of area under the plasma concentration-time curve (AUC) of GV20-0251 when given as monotherapy.",
                    "description": "Characterize pharmacokinetic parameter AUC after IV administration of GV20-0251",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Measure the time to Cmax (Tmax) of GV20-0251 when given as monotherapy.",
                    "description": "Characterize pharmacokinetic parameter Tmax after IV administration of GV20-0251",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Measure of maximum plasma concentration (Cmax) of GV20-0251 when given as monotherapy.",
                    "description": "Characterize pharmacokinetic parameter Cmax after IV administration of GV20-0251",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Measure of Volume of distribution (Vd) of GV20-0251 when given as monotherapy.",
                    "description": "Characterize pharmacokinetic parameter Vd after IV administration of GV20-0251",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Measure of terminal half-life (t1/2) of GV20-0251 when given as monotherapy.",
                    "description": "Characterize pharmacokinetic parameter t1/2 after IV administration of GV20-0251",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Measure of trough concentration (Ctrough) of GV20-0251 when given as monotherapy.",
                    "description": "Characterize pharmacokinetic parameter Ctrough after IV administration of GV20-0251",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Evaluate the Progression-free survival (PFS) of GV20-0251.",
                    "description": "Progression-free survival is defined as the time from the date of study entry (start of treatment) to the first date of objectively determined progressive disease or death from any cause",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Evaluate the Duration of Response (DoR) of GV20-0251.",
                    "description": "Duration of Response is defined as the time from the date when the measurement criteria are met for complete response or partial response (whichever status is recorded first) until the date that recurrence of progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Evaluate the Overall Survival (OS) of GV20-0251.",
                    "description": "Overall Survival is defined as the time from the date of study entry (signing of ICF) to the date of death from any cause.",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Part A & Part B: Evaluate the Disease Control Rate (DCR) of GV20-0251.",
                    "description": "Disease Control Rate following GV20-0251 administration is defined as the proportion of efficacy-eligible participants who have a best response of complete response, partial response, or stable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
                    "timeFrame": "36 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>= 18 years of age\n* Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy\n* Refractory or intolerant to standard therapy(ies)\n* Must have received, be not eligible or decline standard of care therapy\n* One or more metastatic solid tumors that are evaluable or measurable per RECIST v1.1\n* For participants who have received prior treatment with a checkpoint inhibitor there must be documented disease progression\n* ECOG performance status of 0 or 1\n* Life expectancy of \\>=12 weeks\n* Disease-free of active second/secondary or prior malignancies for \u2265 2 years\n* Laboratory test results within the required parameters\n* Women of child bearing potential (WOCBP) and men must agree to use adequate contraception\n* Part B ONLY must include the following tumor types:\n\n  * Cohort B1: bladder urothelial carcinoma\n  * Cohort B2: cholangiocarcinoma\n  * Cohort B3: proficient MMR (pMMR)/MSS adenocarcinoma of the colon or rectum\n  * Cohort B4: proficient MMR (pMMR)/MSS endometrial carcinoma\n  * Cohort B5: deficient MMR (dMMR)/MSI-H endometrial carcinoma\n  * Cohort B6: squamous head and neck carcinoma\n  * Cohort B7: cutaneous melanoma\n  * Cohort B8: non-small cell lung cancer\n\nExclusion Criteria:\n\n* Participant with acute luekemia or CLL\n* Participant with heart disease or unstable arrhythmia\n* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy\n* Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy\n* Known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection\n* History of major organ transplant\n* History of a bone marrow transplant\n* Symptomatic central nervous system (CNS) malignancy or metastasis\n* Serious nonmalignant disease\n* Pregnant or nursing women\n* Treatment with PD-1 and equivalent immune modulators or major surgery prior to the first dose of study medication\n* Participants who are currently receiving any other investigational agent or have received an investigational agent within 4 weeks prior to the first dose of study medication\n* Treatment with any anticancer treatments with 2-weeks prior to the first dose of study medication\n* Radiation for symptomatic lesions must have been completed prior to the first dose of study medication\n* Active substance abuse",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "GV20 Therapeutics",
                    "role": "CONTACT",
                    "phone": "617-256-2846",
                    "email": "clinicaltrials@gv20tx.com"
                }
            ],
            "locations": [
                {
                    "facility": "The Angeles Clinic and Research Institute",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Kristopher Wentzel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Jason Henry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Yale University",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06511",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Patricia LoRusso, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Florida Cancer Specialists & Research Institute, LLC",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Fort Myers",
                    "state": "Florida",
                    "zip": "33916",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Judy Wang, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.62168,
                        "lon": -81.84059
                    }
                },
                {
                    "facility": "Community Health Network, Inc.",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46256",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Bert O'Neil, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Justin Gainor, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "M. Najeeb Al Hallak, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "NYU Langone Health",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Janice Mehnert, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Shivaani Kummar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Verdi Oncology Tennessee, Scri Oncology Partners",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Meredith Pelster, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Oncology Consultants, P.A.",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Jose Peguero, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "The University of Texas M. D. Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Aung Naing, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "GV20 Therapeutics",
                            "role": "CONTACT",
                            "email": "clinicaltrials@gv20tx.com"
                        },
                        {
                            "name": "Alexander Spira, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                },
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3212",
                    "name": "Melanoma, Cutaneous Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}